Anilocus provides comprehensive safety biomarker analysis including molecular, cellular, and protein-based markers for early detection of organ toxicity and adverse effects. Our capabilities include qPCR analysis, flow cytometry, Western blot, and specialized tissue analysis to identify safety signals and support regulatory submissions for drug development programs.